

Case Study – I

Stage IV Melanoma 57 year old male patient

Clinical History	
Jan '16	Diagnosis: Malignant Melanoma
Aug '16	Ungual Lesion Excision
Dec '16	PET-CT, USG: Progression Lymph Node Excision
Jan – Feb '17	Radiotherapy
Mar '17	Lymph Node Excision
Mar '17	PET-CT: Progression

exacta® rationale for therapy selection		
Gene / Pathway / Analysis	Feature	Therapeutic Implication
KIT, PDGFRA	Overexpression	Imatinib
TYMS	Overexpression	5-Fluorouracil
MMP	Overexpression	Doxycycline
EMT, MET	Upregulation	Atorvastatin
WNT	Upregulation	Quercetin
Cell Cycle	Upregulation	Curcumin
AR	Positive (IHC)	Bicalutamid

Benefit from exacta® – recommended therapy

before

Cancer had progressed following 4 lines of therapy.

after

Administration of exacta®: recommended therapy led to regression of cancer.

day 0

day 31